A Phase 2 Study of Canakinumab in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium
Latest Information Update: 08 May 2025
At a glance
- Drugs Canakinumab (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms MPN-RC 122
Most Recent Events
- 25 Mar 2025 Planned number of patients changed from 10 to 14.
- 25 Mar 2025 Status changed from active, no longer recruiting to recruiting.
- 04 Mar 2025 Planned End Date changed from 1 Jul 2026 to 1 Jul 2027.